



BROKING

 bajajbroking.in |  | 

Morning Bell

21 May 2026

Market Commentary

Benchmark indices staged a sharp intraday rebound on 20th May after touching an intraday low of 23,397 during the first hour of the session. The Nifty recovered more than 250 points from lower levels and eventually managed to close above the 23,600 mark, indicating buying interest emerging at lower levels. Crude oil prices witnessed some cooling off from higher levels; however, the Indian Rupee remained under pressure and continued to depreciate amid prevailing global uncertainties.

- At close, the Sensex gained 117.54 points or 0.16% to settle at 75,318.39, while the Nifty advanced 41 points or 0.17% to close at 23,659.00.
- On the sectoral front, markets witnessed a mixed trend. Buying interest was largely seen in Nifty Oil & Gas, Auto, Realty, and Banking stocks, whereas Nifty Media, IT, and FMCG indices emerged as laggards during the session.
- Gift Nifty signals a gap up opening for the Indian Market. Nifty spot in today's session is likely to trade in the range of 23,500-24,000.

Global Updates

- Wall Street closed Wednesday's regular session firmly in green territory, staging a powerful intraday turnaround to reclaim major milestones. A dramatic short-covering wave swept across the floor ahead of the Nvidia print, with small-caps leading the charge as macro desks aggressively squeezed out short positions.
- The positive earnings momentum faces a major macro counterweight from the Federal Reserve. Minutes released from the central bank's latest policy meeting revealed a deeply concerned committee. Rather than debating when to implement a rate cut, a majority of participants explicitly indicated a willingness to introduce further interest rate hikes if sticky cost-push factors keep inflation pinned above the 2% target.
- Asia-Pacific markets opened higher on Thursday morning trade, tracking Wall Street gains, as growing hopes that the Middle East conflict could end soon cooled oil prices

Source: Bloomberg, NSE, NSDL, BSE, Bajaj Broking Research

| Indices | CMP | Daily % | YTD % |
|-----------|-------|---------|--------|
| NIFTY | 23659 | 0.17 | -9.46 |
| BANKNIFTY | 53562 | 0.29 | -10.10 |
| SENSEX | 75318 | 0.16 | -11.62 |
| USDINR | 96.83 | -0.30 | 16.42 |
| INDIA VIX | 18.44 | -1.26 | 94.62 |

| Global Indices | CMP | Daily % | YTD % |
|----------------|---------|---------|-------|
| DOW | 50009.4 | 1.31 | 4.05 |
| S&P500 | 7433.0 | 1.08 | 8.58 |
| NASDAQ | 26270.4 | 1.54 | 13.03 |
| NIKKEI | 61945.3 | 3.58 | 23.06 |
| HANGSENG | 25678 | 0.10 | 0.18 |

| Comm & Gsec | CMP | Daily % | YTD % |
|----------------|--------|---------|-------|
| GOLD (\$) | 4541.6 | 0.14 | 5.17 |
| BR. CRUDE (\$) | 105.5 | 0.42 | 40.82 |
| COPPER (\$) | 6.29 | 2.04 | 56.64 |
| US 10YR (%) | 4.58 | -0.17 | 0.63 |

Asian Market updated on 8:00 AM

Fund flow Activity on NSE BSE & MSEI

| Participant | Cash (in Cr) | MTD (in Cr) | YTD (in Cr) |
|-------------|--------------|-------------|-------------|
| FII | -1597.35 | -25896.97 | -266648.84 |
| DII | 1968.35 | 48369.53 | 350037.62 |


Key Events

India Manufacturing and Services PMI (Preliminary) for the month of May 2026 on 21-05-2026.

Stocks in F&O Ban

SAIL, KAYNES

Position of Market Participants




Index Highlights (DAILY)

| Index | Futures Price | Change | Change (%) | VWAP | Basis | Volume | Change in OI | OI% | ATM IV's | PCR OI |
|------------|---------------|--------|------------|-----------|--------|--------|--------------|------|----------|--------|
| Nifty | 23,668.50 | 56.5 | 0.2% | 23,568.60 | 9.50 | 71,067 | 95,420 | 0.5% | 17.7 | 1.24 |
| Bank Nifty | 53,741.60 | 239.8 | 0.5% | 53,325.56 | 179.40 | 33,310 | 26,970 | 1.0% | 22.5 | 0.8 |


| Price Rise | | OI Gainers | | | | IV Rise | | PCR Rise | |
|------------|---------|------------|---------|-------|---------------|------------|------|------------|----------|
| Symbol | Price % | Symbol | Price % | Oi % | Longshort | Symbol | IV % | Symbol | Change % |
| POWERINDIA | 7.1% | PIIND | -8.0% | 29.0% | Short_Buildup | SAMMAANCAP | 12.6 | POWERINDIA | 0.36 |
| SIEMENS | 4.4% | POLICYBZR | 1.3% | 19.1% | Long_Buildup | SAIL | 8.3 | TIINDIA | 0.30 |
| CGPOWER | 4.2% | MANKIND | 4.0% | 16.1% | Long_Buildup | APOLLOHOSP | 8.2 | DALBHARAT | 0.25 |
| MANKIND | 4.0% | GODFRYPHP | -0.7% | 13.7% | Short_Buildup | POWERINDIA | 7.8 | FINNIFTY | 0.23 |
| ABB | 4.0% | MOTHERSON | 0.7% | 13.1% | Long_Buildup | JUBLFOOD | 7.0 | FORTIS | 0.23 |

| Price Fall | | OI Losers | | | | IV fall | | PCR Fall | |
|------------|---------|------------|---------|-------|----------------|---------|-------|-----------|----------|
| Symbol | Price % | Symbol | Price % | Oi % | Longshort | Symbol | IV % | Symbol | Change % |
| PIIND | -8.0% | NATIONALUM | 0.9% | -4.3% | Short_Covering | PGEL | -15.5 | MANKIND | -0.27 |
| ICICIPRULI | -2.5% | DIVISLAB | -0.3% | -3.0% | Long_Unwinding | MANKIND | -14.8 | MOTHERSON | -0.25 |
| LTM | -2.3% | NUVAMA | 0.5% | -3.0% | Short_Covering | PIIND | -12.2 | PIIND | -0.20 |
| BEL | -2.2% | IOC | 2.3% | -2.8% | Short_Covering | BEL | -12.0 | ICICIGI | -0.15 |
| ICICIGI | -2.0% | SONACOMS | 1.6% | -2.6% | Short_Covering | KAYNES | -10.5 | PGEL | -0.13 |


Index Future Participant wise OI Change




Index Option Participant wise OI Change




Participant wise L/S Ratio



Future Index Long



Future Index Short



Nifty Outlook



Index in the daily chart formed a bullish candle with a lower high and lower low highlighting strong pullback after a gap down opening and closed near the day's high. Index for the third time in the last six sessions has rebounded from near the key support area highlighting buying demand at lower levels.

In today's session Nifty is opening gap up and is expected to again test the major breakdown area of 23,800-23,900. A strength above the breakdown area will signal a pause in the downtrend and will open further upside towards 24,200 levels. While failure to move above the same will signal extension of the last six sessions consolidation in the range of 23,200-23,900.


Index need to start forming higher high and higher low on a sustained basis in the daily chart and a move above the breakdown area of 23,800-23,900 to signal strength.

Nifty has key support at 23,200-23,000 levels being the confluence of the lower band of the 8th April bullish gap area and the 61.8% retracement of the previous pullback (22,182-24,601).

Intraday Support & Resistance

| Index | S2 | S1 | Close | R1 | R2 |
|-------|-------|-------|-------|-------|-------|
| Nifty | 23500 | 23610 | 23659 | 23880 | 24000 |

Nifty Option Chain



- ❑ Aggressive put writing activity has been witnessed across the 23,400 to 23,600 strike range, indicating the formation of a strong support base at lower levels.
- ❑ On the higher side, call writing remains relatively limited, while in-the-money call writers appear to be under pressure. Any unwinding of these trapped call positions could trigger fresh upside momentum in the index.
- ❑ A decisive move above the 23,700 mark is likely to accelerate buying interest, which may drive the Nifty towards the 23,900-24,000 zone in the near term.
- ❑ As long as the index sustains above the crucial support level of 23,600, the overall bias is expected to remain positive. However, a breach below 23,600 may lead to consolidation and profit-booking pressure at higher levels..

Bank Nifty Outlook



Index formed a bullish candle with a lower high and a lower low highlighting strong pullback after a gap down opening and closed near the day's high. Index for the second time in the last three sessions has rebounded from near the key support area highlighting buying demand at lower levels.

Index likely to consolidate in the range of 52,700-54,700. Bank Nifty holding above the key support area of 52,700-52,400 will lead to a pullback towards the recent breakdown area of 54,000 and 54,700.


Index is opening gap up in today's session and is likely to test the breakdown area of 54,400-54,700. However, Index need to form higher high and higher low on a sustained basis in the daily chart and a move above the breakdown area of 54,400-54,700 to signal a pause in the recent downtrend.

Key support is placed at 52,700-52,400 levels being the confluence of the lower band of the 8th April gap area and the 61.8% retracement of the previous pullback (49,955-57,456).

Intraday Support & Resistance

| Index | S2 | S1 | Close | R1 | R2 |
|------------|-------|-------|----------|-------|-------|
| Bank Nifty | 53250 | 53470 | 53562.20 | 54330 | 54700 |

Bank Nifty Option Chain




- ❑ Bank Nifty continues to witness increasing participation from put writers at higher strikes, suggesting that the support base is gradually shifting upward with improving positive sentiment.
- ❑ Meanwhile, significant call writing activity is visible around the 53,500 strike, while Bank Nifty is currently positioned near 53,700. This indicates that call writers are under trapped positions, and any unwinding in these call positions may trigger further upside momentum.
- ❑ Sustaining above current support levels could lead Bank Nifty towards 54,000, followed by 54,500 in the short term.
- ❑ Any intermediate decline should be viewed as a buying opportunity as long as the index holds above its key support zone. However, a decisive breach below support levels may trigger fresh downside pressure and increase market volatility.


News and its impact

| Company/ Industry | News | Impact |
|-----------------------------|--|-----------------|
| SHAILY ENGINEERING | The company has launched a generic version of the Semaglutide Injection in Canada, utilizing its ShailyPen Neo injector platform. | POSITIVE |
| ADITYA BIRLA CAPITAL | The financial services firm plans to issue 11.2 crore shares worth up to Rs 4,000 crore on a preferential basis, comprising Rs 2,880 crore to promoter Grasim, Rs 200 crore to Suryaja Investments, and Rs 920 crore to the IFC. | POSITIVE |
| KRN HEAT EXCHANGERS | The company's subsidiary received approval for its Neemrana plant under the Rajasthan Investment Promotion Scheme (RIPS-2024), which may provide crucial fiscal benefits. | POSITIVE |
| DALMIA BHARAT | The cement maker's board will meet on May 23 to mull fundraising options via QIP, equity, and other instruments | NEUTRAL |
| PACE DIGITEK | The company bagged a Rs 265 crore order from BSNL to supply network infrastructure in Sikkim under the BharatNet Project. | POSITIVE |

Indian ADR % Change



Sector



Mankind Pharma Ltd Q4FY26 Result Update

Result Update

The company delivered a resilient performance during the quarter, with revenue coming in at Rs.34.4 bn, growing 12% YoY despite a marginal 3% sequential decline, while still surpassing consensus estimates by 2%. Operationally, the quarter remained strong as EBITDA stood at Rs.9.3 bn, registering an impressive 36% YoY growth along with a modest sequential improvement, beating estimates by 14%. Profitability continued to strengthen, with EBITDA margins expanding sharply to 27%, up 483 bps YoY and 125 bps QoQ, significantly ahead of consensus expectations by 274 bps, reflecting improved operating efficiency and better cost management. Supported by the robust operating performance, PAT for the quarter stood at Rs.5.6 bn, rising 32% YoY and 35% sequentially, while outperforming street estimates by 28%, highlighting sustained earnings momentum.

Conference Call highlights

FY27 Outlook Remains Strong and Growth-Focused

Mankind Pharma remains optimistic on FY27, guiding for double-digit revenue growth with an ambition to outperform the broader IQVIA market. Management expects adjusted EBITDA margins to improve further to 25.5%–26.5%, supported by better operating leverage, an improving chronic mix, and normalization of integration-related disruptions. The company also remains focused on balance sheet strengthening, with a clear roadmap for debt repayment and a targeted net debt-to-adjusted EBITDA ratio of 0.5x during FY27.

Margin Expansion Driven by Better Mix and Operating Leverage

Profitability remained a key highlight during the quarter, with Q4 FY26 adjusted EBITDA margin expanding sharply to 27.1%. The improvement was largely driven by higher gross margins, operating leverage benefits, and a favorable base effect from elevated launch-related expenses in the corresponding quarter last year.

| Key Data | |
|-------------------|---------------|
| CMP (Rs) | 2,576 |
| Sector / Industry | Healthcare |
| 52 week High/Low | 2,727 / 1,910 |
| Market Cap (bn) | 1063.26 |
| Bloomberg Code | MANKIND IN |
| Face Value (₹) | 1.0 |

| Shareholding % | | | |
|----------------|--------|--------|--------|
| Particulars | Q2FY26 | Q3FY26 | Q4FY26 |
| Promoters | 72.7 | 72.7 | 72.7 |
| FII | 12.8 | 11.3 | 10.2 |
| DII | 11.9 | 13.3 | 14.5 |
| Others | 2.6 | 2.7 | 2.6 |

No Promoter Pledge

| Financial Ratios | | | |
|------------------|------|------|------|
| Ratio | FY24 | FY25 | FY26 |
| ROCE (%) | 22.0 | 14.1 | 10.8 |
| ROE (%) | 22.8 | 16.8 | 12.5 |
| PE (%) | 48.2 | 49.2 | 52.9 |
| P/B(x) | 9.8 | 6.8 | 6.5 |
| Debt/Equity | 0.0 | 0.6 | 0.4 |
| EV/EBITDA | 32.7 | 29.8 | 28.1 |

| NIFTY VS MANKIND:IN | | | | |
|---------------------|-------|-------|-------|-------|
| Returns (%) | 1M | 3M | 6M | 12M |
| Nifty 50 | (3.1) | (7.2) | (9.3) | (4.3) |
| MANKIND | 16.3 | 22.0 | 12.1 | (2.2) |

| Financial Metrics | | | | | | | | | | (Rs in bn) |
|--------------------------|--------------|--------------|---------------|--------------|----------------|--------------|---------------|--------------|--------------|--------------|
| Particulars | Q4FY26 | Q4FY25 | YoY (%) | Q3FY26 | QoQ (%) | Estimates# | Var (%) | FY26 | FY27# | FY28# |
| Revenue | 34.4 | 30.8 | 12% | 35.7 | -3% | 33.6 | 2% | 142.8 | 159.6 | 178.2 |
| EBITDA | 9.3 | 6.8 | 36% | 9.2 | 1% | 8.2 | 14% | 36.2 | 40.6 | 46.5 |
| EBITDA Margin (%) | 27.0% | 22.2% | 483bps | 25.8% | 125bps | 24.3% | 274bps | 25.3% | 25.4% | 26.1% |
| Adj. PAT | 5.6 | 4.3 | 32% | 4.1 | -35% | 4.4 | 28% | 19.4 | 23.7 | 29.2 |
| PAT Margin (%) | 16.2% | 13.8% | 243bps | 11.6% | -463bps | 13.0% | 324bps | 13.6% | 14.9% | 16.4% |
| EPS | 13.4 | 10.2 | | 9.9 | | 10.7 | | 46.34 | 57.5 | 70.8 |

Mankind Pharma Ltd Q4FY26 Result Update

Gross margins improved as the contribution from chronic therapies continued to increase, while disciplined cost management further supported earnings growth. Management emphasized that despite higher investments in R&D, profitability is expected to remain structurally healthy going forward.

Chronic Portfolio Continues to Gain Strength

The company continued to strengthen its chronic therapy presence, with chronic contribution rising to nearly 40% of overall revenues. Management highlighted strong outperformance in key segments such as cardiac and anti-diabetic therapies, supported by rising lifestyle diseases, improving diagnosis rates, and increasing insurance penetration across India. Mankind Pharma maintained its leadership in prescription share and prescriber penetration, reinforcing its growing positioning within the domestic pharmaceutical market.

Strategic Approach Toward GLP-1 Opportunity

Management acknowledged the intense competitive activity emerging in the GLP-1 market but reiterated its preference for a long-term profitability-driven strategy rather than aggressive price competition. The recently launched GLP-1 pen is being targeted primarily toward endocrinologists, while the broader strategy focuses on building adjacent therapy ecosystems and sustainable market positioning. The company indicated that it is not rushing into vial launches or significant price cuts despite increasing industry competition.

BSV Acquisition Strengthening Specialty Capabilities

The BSV acquisition continues to play a transformative role in Mankind Pharma's business model by strengthening its presence in complex biologics and specialty therapies. Management admitted that integration, manpower restructuring, and operational alignment took longer than initially expected; however, these issues are now largely resolved. The acquisition has meaningfully expanded the company's difficult-to-manufacture product portfolio and enhanced its long-term chronic and specialty positioning.

Rising Focus on R&D and Innovation-Led Growth

The company significantly increased its R&D investments during FY26, with expenditure rising to nearly 3% of sales in Q4. Management reiterated that innovation-led growth remains a strategic priority, supported by ongoing clinical studies, biologics development, and specialty product pipelines. Several products currently under development are expected to contribute meaningfully over the next three to five years, positioning the company for a stronger differentiated portfolio in the future.

New Biotech Facility in Vadodara to Drive Future Expansion

As part of its long-term innovation strategy, the company is investing up to INR500 crores in a new biotech facility in Vadodara through its subsidiary Mankind Medicare. The project forms a major component of the company's elevated FY27 CapEx guidance of 6%-7% of revenue. Management views the biotech facility as a strategic platform to expand its biologics capabilities and strengthen participation in specialized therapies over the long term.

Regulatory Progress and Export Capability Expansion

Operationally, the company achieved an important milestone with the Udaipur and Ambarnath plants receiving EUGMP certification, which is expected to enhance export opportunities in semi-regulated markets. The certification strengthens Mankind Pharma's manufacturing credibility and creates a pathway for broader international expansion over time.

Consumer Healthcare and Digital Channels Showing Momentum

The consumer healthcare segment continued to witness improving traction, particularly through modern trade and e-commerce channels. Management highlighted strong growth in digital channels during the quarter, reflecting improving brand visibility, wider reach, and increasing consumer adoption across key OTC brands.

Supply Chain Challenges Managed Through Proactive Measures

Management acknowledged temporary disruptions in raw material sourcing and packaging supplies due to geopolitical tensions and Middle East-related issues. However, the company indicated that precautionary measures and supply chain planning have helped mitigate operational risks, allowing business momentum to remain largely unaffected. Overall, management commentary reflected confidence in sustaining long-term growth through chronic expansion, biologics capability building, disciplined capital allocation, and innovation-led execution.

WEEKLY ECONOMIC CALENDAR

▶▶ 18 - 22 May 2026 ◀◀

China

- Event:** 18 May
- ▶ Chinese Unemployment Rate (Apr)
 - ▶ Chinese Industrial Production YTD (YoY) (Apr)
 - ▶ Industrial Production (YoY) (Apr)

India

- Event:** 20 May
- ▶ S&P Global Services PMI (May)
 - ▶ S&P Global Manufacturing PMI (May)

Japan

- Event:** 19 May
- ▶ GDP (QoQ) (Q1)

United States

- Event:** 20 Nov.
- ▶ FOMC Meeting Minutes
-
- Event:** 21 May
- ▶ FOMC Meeting Minutes
 - ▶ S&P Global Manufacturing PMI (May)
 - ▶ S&P Global Services PMI (May)
-
- Event:** 22 May
- ▶ Fed's Balance Sheet

UK

- Event:** 19 May
- ▶ Unemployment Rate (Mar)
-
- Event:** 20 May
- ▶ CPI (YoY) (Apr)

Nifty 50 stocks – Support & Resistance

| Stock Name | Support 2 | Support 1 | Close | Resistance 1 | Resistance 2 |
|------------|-----------|-----------|----------|--------------|--------------|
| ADANIANT | 2668.40 | 2686.60 | 2704.80 | 2721.50 | 2738.20 |
| ADANIPORTS | 1731.40 | 1752.00 | 1772.60 | 1785.50 | 1798.40 |
| APOLLOHOSP | 7685.50 | 7882.00 | 8078.50 | 8207.50 | 8336.50 |
| ASIANPAINT | 2539.53 | 2569.07 | 2598.60 | 2621.07 | 2643.53 |
| AXISBANK | 1216.00 | 1232.90 | 1249.80 | 1260.40 | 1271.00 |
| BAJAJ-AUTO | 9936.83 | 10199.67 | 10462.50 | 10604.17 | 10745.83 |
| BAJAJFINSV | 1705.33 | 1738.67 | 1772.00 | 1792.67 | 1813.33 |
| BAJFINANCE | 901.43 | 912.27 | 923.10 | 930.12 | 937.13 |
| BEL | 400.43 | 406.87 | 413.30 | 419.87 | 426.43 |
| BHARTIARTL | 1889.23 | 1897.07 | 1904.90 | 1913.37 | 1921.83 |
| CIPLA | 1374.83 | 1387.17 | 1399.50 | 1416.97 | 1434.43 |
| COALINDIA | 449.80 | 454.25 | 458.70 | 461.60 | 464.50 |
| DRREDDY | 1309.43 | 1315.67 | 1321.90 | 1332.07 | 1342.23 |
| EICHERMOT | 6683.17 | 6766.33 | 6849.50 | 6918.83 | 6988.17 |
| ETERNAL | 240.39 | 241.87 | 243.34 | 245.25 | 247.15 |
| GRASIM | 2839.17 | 2905.13 | 2971.10 | 3012.53 | 3053.97 |
| HCLTECH | 1152.47 | 1161.13 | 1169.80 | 1179.73 | 1189.67 |
| HDFCBANK | 751.87 | 755.68 | 759.50 | 762.78 | 766.07 |
| HDFCLIFE | 597.67 | 601.38 | 605.10 | 610.03 | 614.97 |
| HINDALCO | 1019.70 | 1052.60 | 1085.50 | 1104.20 | 1122.90 |
| HINDUNILVR | 2186.50 | 2197.90 | 2209.30 | 2223.80 | 2238.30 |
| ICICIBANK | 1217.03 | 1227.17 | 1237.30 | 1243.57 | 1249.83 |
| INDIGO | 4136.20 | 4200.40 | 4264.60 | 4306.40 | 4348.20 |
| INFY | 1173.17 | 1183.43 | 1193.70 | 1205.43 | 1217.17 |
| ITC | 304.35 | 305.95 | 307.55 | 309.40 | 311.25 |
| JIOFIN | 227.14 | 230.91 | 234.67 | 236.95 | 239.22 |
| JSWSTEEL | 1250.40 | 1266.80 | 1283.20 | 1294.30 | 1305.40 |
| KOTAKBANK | 373.43 | 378.32 | 383.20 | 386.07 | 388.93 |
| LT | 3852.03 | 3881.37 | 3910.70 | 3941.77 | 3972.83 |
| M&M | 2989.53 | 3055.87 | 3122.20 | 3165.67 | 3209.13 |
| MARUTI | 12623.67 | 12813.33 | 13003.00 | 13132.33 | 13261.67 |
| MAXHEALTH | 1042.23 | 1058.97 | 1075.70 | 1086.22 | 1096.73 |
| NESTLEIND | 1386.77 | 1403.43 | 1420.10 | 1431.83 | 1443.57 |
| NTPC | 380.58 | 386.52 | 392.45 | 395.87 | 399.28 |
| ONGC | 290.07 | 294.18 | 298.30 | 302.08 | 305.87 |
| POWERGRID | 292.17 | 296.03 | 299.90 | 302.28 | 304.67 |
| RELIANCE | 1294.77 | 1327.23 | 1359.70 | 1377.53 | 1395.37 |
| SBILIFE | 1841.27 | 1852.73 | 1864.20 | 1879.03 | 1893.87 |
| SBIN | 926.97 | 938.93 | 950.90 | 958.93 | 966.97 |
| SHRIRAMFIN | 908.18 | 915.82 | 923.45 | 928.27 | 933.08 |
| SUNPHARMA | 1860.83 | 1870.57 | 1880.30 | 1891.47 | 1902.63 |
| TATACONSUM | 1184.10 | 1196.40 | 1208.70 | 1218.80 | 1228.90 |
| TATASTEEL | 201.39 | 204.20 | 207.01 | 208.66 | 210.31 |
| TCS | 2304.87 | 2316.13 | 2327.40 | 2340.33 | 2353.27 |
| TECHM | 1408.27 | 1423.63 | 1439.00 | 1465.43 | 1491.87 |
| TITAN | 4028.33 | 4067.37 | 4106.40 | 4131.07 | 4155.73 |
| TMPV | 351.88 | 356.57 | 361.25 | 365.47 | 369.68 |
| TRENT | 3986.63 | 4043.27 | 4099.90 | 4135.27 | 4170.63 |
| ULTRACEMCO | 11131.00 | 11270.00 | 11409.00 | 11489.00 | 11569.00 |
| WIPRO | 192.43 | 194.77 | 197.12 | 198.70 | 200.29 |



Disclaimer

Bajaj Financial Securities Limited (BFSL) is a subsidiary of Bajaj Finance Limited (BFL) and a step-down subsidiary of Bajaj Finserv Limited. The parent entities of BFSL are public listed companies and have various subsidiaries engaged in the business of NBFC, Housing Finance, Insurance, AMC etc. BFSL is *inter alia* SEBI registered Stock-Broker, Depository Participant and distributor of financial products.

Analyst Certification: We/I, Sumit Singhania, Pradeep Kasat, Anand Shendge, Pabitra Mukherjee, Vikas Vyas, Nisarg Shah, Shashwat Singh, Raunaq Murarka authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Registration Details

Reg Office: Bajaj Auto Limited Complex, Mumbai –Pune Road Akurdi Pune 411035. | Corp. Office: Bajaj Financial Securities Ltd., 1st Floor, Mantri IT Park, Tower B, Unit No 9, Viman Nagar, Pune, Maharashtra 411014. SEBI Registration No.: INZ000218931 | BSE Cash/F&O (Member ID: 6706) | NSE Cash/F&O (Member ID: 90177) | DP registration No: IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN – 163403 | AMFI Registration No.: ARN – 163403 | Research Analyst Regn: INH00010043.

Compliance Officer: Mr. Boudhayan Ghosh (For Broking/DP/Research) email@ compliance_sec@bajajbroking.in | Contact No.: 020-4857 4486 |

Disclaimers & Disclosures- SEBI Research Analysts Regulations, 2014

Investments in the securities market are subject to market risk, read all related documents carefully before investing.

Kindly refer to <https://www.bajajbroking.in/disclaimer> for detailed disclaimer and risk factors.

There were no instances of non-compliance by BFSL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last 3 years. The information/opinion in this report are as on date and there can be no assurance that future results or events will be consistent with this information/opinion. This report is subject to change without any notice. This report and information are strictly confidential and is being furnished to you solely for your information and may not be altered in any way, transmitted to, copied or distributed, in part or in whole to any other person or to media or reproduced in any form without prior written consent of BFSL. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any jurisdiction including but not limited to USA and Canada, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject BFSL and associates / group companies to any registration or licensing requirements within such jurisdiction.

BFSL, its directors, officers, agents, representative, associates / group companies shall not be in any way responsible for any loss or damage (direct, indirect, special or consequential) that may arise to any person from any inadvertent error, use of this report/information contained in this report. The report is based on information obtained in good faith from public sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness is guaranteed. This should not be construed as invitation or solicitation to do business with BFSL.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance.

The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. BFSL offers its research services to clients as well as our prospects, though disseminated, to all customers simultaneously, not all customers may receive this report at the same time. BFSL will not treat recipients as customers by virtue of their receiving this report.

BFSL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

BFSL or its associates may have received compensation from the subject company in the past 12 months in respect of managing/co-managed public offering of securities, for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. BFSL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. BFSL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report.

Research analyst or his/her relative or BFSL's associates may have financial interest in the subject company. BFSL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Research analyst has served as an officer, director or employee of subject Company: No | Bajaj Broking has financial interest in the subject companies: No | Bajaj Broking's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report. Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No | Bajaj Broking has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No | Subject company may have been client during twelve months preceding the date of distribution of the research report.

A graph of daily closing prices of the securities is also available at www.nseindia.com. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."

For more queries reach out to : Name - Bajaj Broking Research Team | Email Id - researchdesk@bajajbroking.in

| | | | | |
|----------------------------|---|---|--|---|
| Research Analysts : | Sumit Singhania (Research Head) | Pradeep Kasat (Sr VP Technical Analyst) | Anand Shendge (DVP Derivative Analyst) | Pabitra Mukherjee (AVP Technical Analyst) |
| | Vikas Vyas (Derivative Analyst) | Raunaq Murarka (Derivatives Analyst) | Nisarg Shah (Fundamental Analyst) | Shashwat Singh (Fundamental Analyst) |